{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:50:30Z","timestamp":1787237430679,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10557-020-07118-2","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T05:08:55Z","timestamp":1609909735000},"page":"371-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of Angiotensin II Receptor Blockers on Ventricular Hypertrophy in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"36","author":[{"given":"Ye","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki K.","family":"Wing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanan","family":"Supasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-3129","authenticated-orcid":false,"given":"Kanhua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"4","key":"7118_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1006\/jmcc.2001.1340","volume":"33","author":"AJ Marian","year":"2001","unstructured":"Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33(4):655\u201370.","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"7118_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","volume":"1","author":"YJ Shimada","year":"2013","unstructured":"Shimada YJ, Passeri JJ, Baggish AL, O'Callaghan C, Lowry PA, Yannekis G, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(6):480\u20137.","journal-title":"JACC Heart Fail"},{"issue":"9","key":"7118_CR3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ejhf.541","volume":"18","author":"E Ammirati","year":"2016","unstructured":"Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106\u201318.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"7118_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","volume":"103","author":"DS Lim","year":"2001","unstructured":"Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103(6):789\u201391.","journal-title":"Circulation"},{"issue":"10","key":"7118_CR5","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1172\/JCI42028","volume":"120","author":"P Teekakirikul","year":"2010","unstructured":"Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2. J Clin Invest. 2010;120(10):3520\u20139.","journal-title":"J Clin Invest"},{"issue":"12","key":"7118_CR6","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1253\/circj.CJ-10-0482","volume":"74","author":"A Funada","year":"2010","unstructured":"Funada A, Konno T, Fujino N, Muramoto A, Hayashi K, Tsubokawa T, et al. Impact of renin-angiotensin system polymorphisms on development of systolic dysfunction in hypertrophic cardiomyopathy. Evidence from a study of genotyped patients. Circ J. 2010;74(12):2674\u201380.","journal-title":"Circ J"},{"issue":"6","key":"7118_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1536\/ihj.48.715","volume":"48","author":"T Yamazaki","year":"2007","unstructured":"Yamazaki T, Suzuki J, Shimamoto R, Tsuji T, Ohmoto-Sekine Y, Ohtomo K, et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. Int Heart J. 2007;48(6):715\u201324.","journal-title":"Int Heart J"},{"issue":"11","key":"7118_CR8","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.amjcard.2005.07.065","volume":"96","author":"AQ Araujo","year":"2005","unstructured":"Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2005;96(11):1563\u20137.","journal-title":"Am J Cardiol"},{"issue":"2","key":"7118_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","volume":"3","author":"A Axelsson","year":"2015","unstructured":"Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"7118_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/heartjnl-2015-308343","volume":"102","author":"A Axelsson","year":"2016","unstructured":"Axelsson A, Iversen K, Vejlstrup N, Ho CY, Havndrup O, Kofoed KF, et al. Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. Heart. 2016;102(4):285\u201391.","journal-title":"Heart"},{"issue":"39","key":"7118_CR11","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733\u201379.","journal-title":"Eur Heart J"},{"issue":"7","key":"7118_CR12","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"1","key":"7118_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"issue":"2","key":"7118_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1148\/radiology.169.2.2971985","volume":"169","author":"J Katz","year":"1988","unstructured":"Katz J, Milliken MC, Stray-Gundersen J, Buja LM, Parkey RW, Mitchell JH, et al. Estimation of human myocardial mass with MR imaging. Radiology. 1988;169(2):495\u20138.","journal-title":"Radiology"},{"issue":"10","key":"7118_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1253\/circj.69.1244","volume":"69","author":"H Kawano","year":"2005","unstructured":"Kawano H, Toda G, Nakamizo R, Koide Y, Seto S, Yano K. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J. 2005;69(10):1244\u20138.","journal-title":"Circ J"},{"issue":"1","key":"7118_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","volume":"11","author":"M Penicka","year":"2009","unstructured":"Penicka M, Gregor P, Kerekes R, Marek D, Curila K, Krupicka J, et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn. 2009;11(1):35\u201341.","journal-title":"J Mol Diagn"},{"issue":"2","key":"7118_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/hr.2009.192","volume":"33","author":"T Tsutamoto","year":"2010","unstructured":"Tsutamoto T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T, et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res. 2010;33(2):118\u201322.","journal-title":"Hypertens Res"},{"issue":"2","key":"7118_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ajh.2007.47","volume":"21","author":"AM Grandi","year":"2008","unstructured":"Grandi AM, Solbiati F, Laurita E, Maresca AM, Nicolini E, Marchesi C, et al. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens. 2008;21(2):231\u20137.","journal-title":"Am J Hypertens"},{"issue":"9","key":"7118_CR19","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1161\/01.STR.0000236839.69658.c5","volume":"37","author":"B Ariff","year":"2006","unstructured":"Ariff B, Zambanini A, Vamadeva S, Barratt D, Xu Y, Sever P, et al. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke. 2006;37(9):2381\u20134.","journal-title":"Stroke"},{"issue":"2","key":"7118_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ajh\/5.2.95","volume":"5","author":"B Dahlof","year":"1992","unstructured":"Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95\u2013110.","journal-title":"Am J Hypertens"},{"issue":"3","key":"7118_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ndt\/13.3.564","volume":"13","author":"RE Schmieder","year":"1998","unstructured":"Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13(3):564\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"7118_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","volume":"115","author":"AU Klingbeil","year":"2003","unstructured":"Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41\u20136.","journal-title":"Am J Med"},{"issue":"5","key":"7118_CR23","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","volume":"54","author":"RH Fagard","year":"2009","unstructured":"Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54(5):1084\u201391.","journal-title":"Hypertension"},{"issue":"11","key":"7118_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","volume":"110","author":"RB Devereux","year":"2004","unstructured":"Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110(11):1456\u201362.","journal-title":"Circulation"},{"issue":"9311","key":"7118_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995\u20131003.","journal-title":"Lancet"},{"key":"7118_CR26","first-page":"195","volume":"7","author":"C Roma-Rodrigues","year":"2014","unstructured":"Roma-Rodrigues C, Fernandes AR. Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy. Appl Clin Genet. 2014;7:195\u2013208.","journal-title":"Appl Clin Genet"},{"issue":"7","key":"7118_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1524-6175.2006.05366.x","volume":"8","author":"SE Kjeldsen","year":"2006","unstructured":"Kjeldsen SE, Strand A, Julius S, Okin PM. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy. J Clin Hypertens (Greenwich). 2006;8(7):487\u201392.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"7118_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/heart.87.3.270","volume":"87","author":"JR Ortlepp","year":"2002","unstructured":"Ortlepp JR, Vosberg HP, Reith S, Ohme F, Mahon NG, Schroder D, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart. 2002;87(3):270\u20135.","journal-title":"Heart"},{"issue":"22","key":"7118_CR29","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1093\/eurheartj\/ehi438","volume":"26","author":"MJ Perkins","year":"2005","unstructured":"Perkins MJ, Van Driest SL, Ellsworth EG, Will ML, Gersh BJ, Ommen SR, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J. 2005;26(22):2457\u201362.","journal-title":"Eur Heart J"},{"issue":"1","key":"7118_CR30","doi-asserted-by":"publisher","first-page":"9995","DOI":"10.1038\/s41598-018-27049-1","volume":"8","author":"M Jiang","year":"2018","unstructured":"Jiang M, Wang Z, Su X, Gong X, Pu J, Wu L, et al. The significance of interstitial fibrosis on left ventricular function in hypertensive versus hypertrophic cardiomyopathy. Sci Rep. 2018;8(1):9995.","journal-title":"Sci Rep"},{"issue":"2","key":"7118_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s12265-019-09911-3","volume":"13","author":"MA Losi","year":"2020","unstructured":"Losi MA, Imbriaco M, Canciello G, Pacelli F, Di Nardo C, Lombardi R, et al. Left ventricular mass in hypertrophic cardiomyopathy assessed by 2D-echocardiography: validation with magnetic resonance imaging. J Cardiovasc Transl Res. 2020;13(2):238\u201344.","journal-title":"J Cardiovasc Transl Res"},{"issue":"6","key":"7118_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","volume":"57","author":"RB Devereux","year":"1986","unstructured":"Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450\u20138.","journal-title":"Am J Cardiol"},{"issue":"5","key":"7118_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","volume":"21","author":"PM Seferovic","year":"2019","unstructured":"Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553\u201376.","journal-title":"Eur J Heart Fail"},{"key":"7118_CR34","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ijcard.2016.11.162","volume":"228","author":"TF Haland","year":"2017","unstructured":"Haland TF, Saberniak J, Leren IS, Edvardsen T, Haugaa KH. Echocardiographic comparison between left ventricular non-compaction and hypertrophic cardiomyopathy. Int J Cardiol. 2017;228:900\u20135.","journal-title":"Int J Cardiol"},{"issue":"1","key":"7118_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12947-016-0072-5","volume":"14","author":"VM Parato","year":"2016","unstructured":"Parato VM, Antoncecchi V, Sozzi F, Marazia S, Zito A, Maiello M, et al. Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy. Cardiovasc Ultrasound. 2016;14(1):30.","journal-title":"Cardiovasc Ultrasound"},{"key":"7118_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ahj.2017.02.008","volume":"187","author":"CY Ho","year":"2017","unstructured":"Ho CY, McMurray JV, Cirino AL, Colan SD, Day SM, Desai AS, et al. The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial. Am Heart J. 2017;187:145\u201355.","journal-title":"Am Heart J"},{"issue":"10253","key":"7118_CR37","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759\u201369.","journal-title":"Lancet"},{"issue":"3","key":"7118_CR38","doi-asserted-by":"crossref","first-page":"S1: 596a","DOI":"10.1016\/j.bpj.2019.11.3225","volume":"118","author":"JJ Hartman","year":"2020","unstructured":"Hartman JJ, Hwee DT, Wang J, Wu Y, Schaletzky J, Paliwal P, et al. Characterization of the cardiac myosin inhibitor CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy. Biophys J. 2020;118(3):S1: 596a.","journal-title":"Biophys J"},{"key":"7118_CR39","unstructured":"Cytokinetics. REDWOOD-HCM: Randomized Evaluation of Dosing With CK-3773274 in Obstructive Outflow Disease in HCM (REDWOOD-HCM). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04219826. NLM Identifier NCT04219826. Accessed November 2, 2020."},{"issue":"1","key":"7118_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamacardio.2019.4638","volume":"5","author":"LA Eberly","year":"2020","unstructured":"Eberly LA, Day SM, Ashley EA, Jacoby DL, Jefferies JL, Colan SD, et al. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2020;5(1):83\u201391.","journal-title":"JAMA Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07118-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T06:13:08Z","timestamp":1647929588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07118-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["7118"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07118-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"18 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}